Xylazine, reported as an adulterant in an increasing number of illicit drug mixtures, has also been detected in a growing number of overdose deaths. It is commonly encountered in combination with fentanyl but has also been detected in mixtures containing cocaine, heroin, and a variety of other drugs. However, xylazine...

The U.S. Drug Enforcement Administration has released the 2022 edition of Drugs of Abuse, A DEA Resource Guide , which is designed to be a reliable resource on the most commonly used and misused drugs in the United States. Released on a periodic basis, Drugs of Abuse provides important science-based...

The DEA’s Fentanyl Profiling Program (FPP) performs in-depth chemical analyses on fentanyl and fentanyl-related samples obtained from seizures throughout the United States. This report summarizes the findings for these analyses for Calendar Year 2021. FPP data is not intended to reflect U.S. market share, but is rather a snapshot of...

La DEA está observando un repunte en todo el país de sucesos de sobredosis masivas relacionados con el fentanilo que implican tres o más sobredosis que ocurren cerca en el tiempo en el mismo lugar. Solo en los dos últimos meses, al menos 7 eventos confirmados de sobredosis masiva en...

The DEA is seeing a nationwide spike in fentanyl-related mass-overdose events involving three or more overdoses occurring close in time at the same location. In just the past two months, there have been at least 7 confirmed mass overdose events across the United States resulting in 58 overdoses and 29...

DEA officials report a dramatic rise in the number of fake pills containing at least 2 mg of fentanyl, which is considered a deadly dose.

What is it? Many counterfeit pills are made to look like prescription opioids – such as oxycodone (Oxycontin®, Percocet®), hydrocodone (Vicodin®), and alprazolam (Xanax®); or stimulants like amphetamines (Adderall®) – but contain fentanyl or methamphetamine. Criminal drug networks are mass-producing fake pills and falsely marketing them as legitimate prescription pills...

The increasing availability of illicit opioids is the most significant drug threat in Pennsylvania. The Philadelphia Field Division (PFD) monitors this threat closely, periodically reviewing multiple data indicators, in conjunction with investigative information, to continually assess the threat, then share analytical findings with stakeholders in federal, state, and municipal governments.

The Drug Enforcement Administration (DEA) Philadelphia Field Division (PFD) is advising law enforcement and public health counterparts of the increased availability of counterfeit controlled prescription drugs (CPDs) – commonly sold as legitimate CPDs with most containing fentanyl/ fentanyl-related compounds (FRC) – in Pennsylvania and Delaware.

The PDIP strives to maintain situational awareness of the threat posed by prescription opioids in Pennsylvania, and to share these analyses with stakeholders in federal, state, and municipal governments. In 2013, the PDIP published a Pharmaceutical Threat Assessment for Pennsylvania that found prescription opioid availability and abuse at epidemic levels...